Stoke Therapeutics (NASDAQ:STOK) Insider Sells $152,545.32 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 5,931 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $25.72, for a total transaction of $152,545.32. Following the completion of the transaction, the insider owned 7,195 shares of the company’s stock, valued at approximately $185,055.40. The trade was a 45.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Tuesday, September 2nd, Barry Ticho sold 5,501 shares of Stoke Therapeutics stock. The shares were sold at an average price of $19.87, for a total transaction of $109,304.87.

Stoke Therapeutics Stock Down 9.9%

STOK traded down $2.52 during midday trading on Wednesday, hitting $22.82. 2,132,529 shares of the company traded hands, compared to its average volume of 903,559. The company’s 50-day moving average is $26.28 and its 200 day moving average is $16.99. The firm has a market capitalization of $1.25 billion, a PE ratio of 26.85 and a beta of 1.32. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The firm had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Needham & Company LLC increased their price objective on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of Stoke Therapeutics in a research report on Wednesday, October 8th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday. Finally, Jefferies Financial Group initiated coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They set a “buy” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently bought and sold shares of STOK. Siren L.L.C. boosted its stake in Stoke Therapeutics by 12.4% during the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock worth $14,945,000 after buying an additional 247,347 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in Stoke Therapeutics in the 2nd quarter worth about $402,000. KLP Kapitalforvaltning AS boosted its stake in shares of Stoke Therapeutics by 131.6% during the second quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock valued at $150,000 after purchasing an additional 7,500 shares during the period. Invesco Ltd. boosted its stake in shares of Stoke Therapeutics by 117.0% during the first quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock valued at $174,000 after purchasing an additional 14,118 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Stoke Therapeutics during the first quarter valued at $2,376,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.